Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
170
resultados
Última actualización
22/03/2026 [07:55:00]
Resultados 125 a 150 de 170
Resumen de: WO2026025015A1
The present disclosure generally relates to the treatment of subjects having Parkinson's disease or at risk of developing Parkinson's disease by administering a SIM BHLH Transcription Factor 2 (SIM2) agonist to the subject.
Resumen de: US20260027157A1
Methods to alleviate or treat Alzheimer's Disease or a neurological disorder or disorder, or to alleviate the symptoms of each thereof are provided, the methods comprising administering an effective amount of (HSPC) or a population of HSPCs to the subject, that are optionally gene-corrected prior to administration and that will differentiate on healthy microglia cells in the brain. The cells are capable of decreasing amyloid plaques and inflammation.
Resumen de: AU2024288766A1
The invention relates to liposome-encapsulated apomorphine, processes for preparing said liposome-encapsulated apomorphine and to the use of such in the treatment of Parkinson's disease.
Resumen de: AU2025205168A1
An anti-DAT antibody which is formed from a gene comprising SEQ ID No:2 after transcription and translation. The anti-DAT antibody of the present invention can be made into a composition capable of crossing the blood-brain barrier, and specifically binding to dopamine nerve cells, and achieving excellent efficacy in reducing the accumulation of α- syn in the striatum and delaying the course of Parkinson's disease. An anti-DAT antibody which is formed from a gene comprising SEQ ID No:2 after transcription and translation. The anti-DAT antibody of the present invention can be made into a composition capable of crossing the blood-brain barrier, and specifically binding to dopamine nerve cells, and achieving excellent efficacy in reducing the accumulation of - syn in the striatum and delaying the course of Parkinson's disease. ul u l
Resumen de: AU2025205167A1
A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease. A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.20 ul u l
Resumen de: AU2024238511A1
The present disclosure relates to biomarkers and uses thereof in methods for selecting a patient diagnosed with amyotrophic lateral sclerosis (ALS) for an ALS therapy. The present disclosure further relates to methods for identifying the severity of ALS in a patient, treating an ALS patient, and monitoring efficacy of an ALS treatment.
Resumen de: EP4685158A1
The present invention relates to the field of neurodegenerative diseases, in particular Alzheimer's disease. The present invention further relates to fibrillary Apolipoprotein E (ApoE) for use in a method of treatment and/or prevention of a neurodegenerative disease and methods of producing said fibrillary ApoE. Moreover, the present invention relates to an antigen-binding peptide specifically binding to fibrillary ApoE, preferably human ApoE, a method of generating said antigen-binding peptide, and its use in a method of treatment and/or prevention and/or diagnosis of a neurodegenerative disease in a patient in need thereof.
Resumen de: CN121401437A
The invention discloses ultrasonic response ZnS (at) Lf piezoelectric nanoparticles as well as a preparation method and application thereof, and relates to the technical field of piezoelectric materials. The ultrasonic response ZnS (at) Lf piezoelectric nano-particle comprises a ZnS nano-particle and lactoferrin loaded on the surface of the ZnS nano-particle. According to the invention, lactoferrin is used as a potent brain-targeting ligand, and passes through a blood-brain barrier to be accumulated in brain parenchyma under the cell transfer action of brain capillary endothelial cells. ZnS nano particles release charges under the ultrasonic action, an electric signal activates a voltage-gated calcium ion channel and extracellular calcium ion influx, calcium ion/calmodulin kinase induces tyrosine hydroxylase (TH) phosphorylation, the activity of tyrosine hydroxylase is enhanced, tyrosine hydroxylase is a key enzyme for generating dopamine, and the activity of the tyrosine hydroxylase is enhanced. Therefore, more tyrosine in vivo is converted into neurotransmitter dopamine under the action of the enzyme. Finally, the regeneration of dopaminergic neurons is realized, so that the Parkinson's disease is effectively improved.
Resumen de: CN121405631A
The invention discloses an edaravone structure-based aromatic alkylamine ferroptosis inhibitor as well as a preparation method and application thereof. The structural formula of the ferroptosis inhibitor is shown as a formula I, a formula II or a formula III. The ferroptosis inhibitor has relatively strong ROS (reactive oxygen species) removal capability and a lipid peroxidation inhibition effect; ferroptosis caused by a ferroptosis inducer can be inhibited; cerebral ischemia and nerve injury caused by cerebral ischemia can be relieved, and symptoms of neurological diseases such as Parkinson's syndrome and the like can be relieved. Therefore, based on the ferrostain-1/edaravone structure, the aromatic alkylamine ferroptosis inhibitor provided by the invention can play a synergistic effect through multiple effects to treat ferroptosis related diseases, can also expand the application of edaravone, and provides a candidate compound for subsequent drug research and development.
Resumen de: CN121401288A
The invention discloses an application of a miR-570-3p (micro Ribonucleic Acid) inhibitor. Belongs to the technical field of biological medicine, the research on AD pathogenesis for the first time discovers that the expression of miR-570-3p is remarkably up-regulated in AD patients, and further cell experiments discover that the change of cell viability, apoptosis and ROS caused by A beta1-42 is remarkably improved by inhibiting the expression of miR-570-3p so as to play a role in treating AD. A beta1-42 is a core component of amyloid plaque in the brain of an AD patient, and is widely applied to construction of AD cell models and animal models so as to research pathogenesis and drug evaluation of AD. The inhibitor is used for preparing a medicine for treating the Alzheimer's disease, and the nucleotide sequence of the inhibitor is GCAAAGGUAAUUGCUGUUUUCG.
Resumen de: CN121405635A
The invention discloses an A beta aggregation inhibitor as well as a preparation method and application thereof, and belongs to the technical field of medicines. The structural formula of the aryl imidazole compound is shown in the specification, in-vivo and in-vitro experiments prove that the compound can inhibit the aggregation and fibrosis process of beta-amyloid protein A beta 42, reduce the neurotoxicity of the beta-amyloid protein A beta 42 and play a role in neuroprotection; nematode model experiments prove that the compound can prolong the life of Alzheimer's disease model nematodes, delay disease-related phenotype progression, improve the motor ability of the Alzheimer's disease model nematodes, improve the nerve function state of the Alzheimer's disease model nematodes, increase the survival rate of nerve cells induced by ischemia and hypoxia and reduce cell death. The aryl imidazole compound prepared by the invention can be used as an A beta aggregation inhibitor to be applied to anti-aging and neurodegenerative diseases such as Alzheimer's disease, and has good application prospect and conversion value.
Resumen de: CN121405626A
The invention relates to the technical field of biological medicine, the embodiment of the invention provides a single small molecule capable of inducing NeuroD1 expression of cells such as a neural stem cell line and astrocytes, the astrocytes are reprogrammed into inducible neurons in vitro, and the small molecule can be suitable for treatment of neurodegenerative diseases so as to supplement missing neurons. In addition, the compound provided by the invention has an acetylcholin esterase activity inhibition effect, and can relieve symptoms of neurodegenerative diseases such as Alzheimer's disease, even Parkinson's disease and the like. The compound has small in-vitro cell toxic and side effects, better water solubility and better physicochemical properties, and is suitable for preparing various solid and liquid preparations, including development into oral preparations.
Resumen de: CN121405653A
The invention discloses an aromatic alkylamine ferroptosis inhibitor based on a butylphthalide structure and a preparation method and application thereof. The chemical structural formula of the ferroptosis inhibitor is shown as a formula 1 or a formula 2. The ferroptosis inhibitor can inhibit ferroptosis caused by a ferroptosis inducer and can reduce the level of active oxygen in cells. Nerve injury caused by cerebral ischemia reperfusion can be relieved, and symptoms of neurological diseases such as Alzheimer's disease and Parkinson's disease can be relieved; compared with a ferroptosis inhibitor Ferrostatin-1, the aryl alkyl amine compound disclosed by the invention has better metabolic stability and is suitable for in-vivo drug effect evaluation. Therefore, the novel aryl alkyl amine compound provided by the invention has a very good application value in treatment of neurological diseases related to ferroptosis.
Resumen de: CN121371191A
The invention discloses a nasal delivery PF4 mRNA delivery system, the nasal delivery PF4 mRNA delivery system comprises a mesenchymal stem cell exosome encapsulated with PF4 mRNA and a pharmaceutically acceptable auxiliary material, and the nucleotide sequence of the PF4 mRNA is as shown in SEQ NO: 1. According to the invention, the MSC-Exo is utilized to deliver the PF4 mRNA, and the administration is carried out in a nasal administration manner, so that the MSC-Exo encapsulated with the PF4 mRNA can bypass BBB to efficiently enter the brain through olfactory bulbs, and the PF4 mRNA and the MSC-Exo can play a synergistic effect, so that the inflammatory reaction induced by A beta is obviously alleviated, and the cognitive level of AD mice is improved. The nasal delivery PF4 mRNA delivery system provided by the invention can be applied to preparation of drugs for treating neurodegenerative diseases, and preferably can be applied to preparation of drugs for treating Alzheimer's disease.
Resumen de: CN121378241A
The invention relates to a PROTAC compound targeting DAPK1 as well as a preparation method and application of the PROTAC compound. The structural formula of the PROTAC compound is X-Y-Z; wherein X represents a ligand of DAPK1 protein, Z represents a ligand of E3 ligase, and Y represents a chain connecting X and Z. The compound can be used for treating or preventing Alzheimer's disease.
Resumen de: CN121398833A
Described herein are methods for treating AD (e.g., mild AD, moderate AD, or severe or advanced AD) comprising administering a therapeutically effective amount of WS635 to a subject in need of such treatment or having been determined to be in need of such treatment.
Resumen de: CN121370921A
The invention is applicable to the technical field of biological medicines, and provides application of ginsenoside CK in preparation of a medicine for preventing or treating Alzheimer's disease. Experiments prove that the ginsenoside CK can significantly improve the spatial learning and memory ability of AD model animals and relieve anxiety behaviors of the AD model animals; the deposition of brain tissue hippocampal Abeta (1-42) protein is effectively reduced, and the key molecular pathology of AD is relieved from the source; the level of key inflammatory factors in brain tissues and serum is strongly inhibited, and AD-related chronic neuroinflammation is controlled; according to the present invention, the CK has the specific protection effect on the hippocampal neuron structure, such that the CK can be adopted as the multi-target treatment agent so as to prevent and/or treat the Alzheimer's disease.
Resumen de: CN121378212A
The invention discloses a 2-(piperidinyl) pyridazinone compound (I), pharmaceutically acceptable salts thereof, a preparation method of the 2-(piperidinyl) pyridazinone compound, a pharmaceutical composition of the 2-(piperidinyl) pyridazinone compound and application of the 2-(piperidinyl) pyridazinone compound in preparation of drugs for treating and/or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;
Resumen de: CN121378240A
The invention discloses a PROTAC molecule for targeting Tau protein degradation based on methylene blue and an application of the PROTAC molecule. The PROTAC molecule is a bifunctional compound and is composed of Tau protein-targeted methylene blue or a derivative ligand thereof, an E3 ubiquitin ligase ligand and a connecting chain for connecting the two ligands. According to the present invention, the affinity characteristic of the methylene blue or the derivative thereof to the Tau protein is utilized, and the methylene blue or the derivative thereof is adopted as the target protein binding unit of the PROTAC molecule so as to specifically degrade the Tau protein through the ubiquitin-proteasome system; the PROTAC molecule has dual functions of inhibiting Tau protein aggregation and promoting Tau protein degradation, and can effectively reduce the level of total Tau protein and pathological phosphorylated Tau protein in cells. The PROTAC molecule provided by the invention can be used for preparing medicines for preventing and/or treating neurodegenerative diseases such as Alzheimer's disease and the like.
Resumen de: CN121378368A
The invention discloses a novel benzofuran component in eupatorium chinense and application of the benzofuran component in anti-inflammatory activity. The obtained compound is separated from an eupatorium chinense extract. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, Sephadex LH-20 gel column chromatography, high performance liquid chromatography and other methods. According to the present invention, all the separated compounds and the analogues thereof have good inhibition activity on target cyclooxygenase-2 of inflammation-related diseases, and have good inhibition activity on COX-2 enzyme, and the molecular docking experiment results show that the compounds and the target proteins have good binding energy. Therefore, the compound can be used for preparing drugs for treating inflammatory related diseases, or anti-inflammatory and analgesic drugs, or tumor drugs by inhibiting COX-2 enzyme, such as drugs for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, Alzheimer's disease and the like, and related natural lead compounds are provided.
Resumen de: CN121370908A
The invention discloses an application of a steroid-like hormone delta 4-dafraronic acid (delta 4-DA) in preparation of a medicine for preventing or treating a neurodegenerative disease. The steroid-like hormone delta 4-dafraronic acid (delta 4-DA) is used for preventing or treating the neurodegenerative disease. The invention proves that the steroid-like hormone delta 4-DA can obviously slow down the degeneration process of dopaminergic neurons of a nematode PD model, so that the steroid-like hormone delta 4-DA can be used for preventing and treating neurodegenerative diseases (especially Parkinson's syndrome).
Resumen de: CN121378242A
The invention relates to a compound for targeted degradation of alpha-synuclein or a pharmaceutically acceptable salt thereof as well as a preparation method and application of the compound. The structural formula of the compound for targeted degradation of alpha-synuclein is shown as a general formula (I), the compound can degrade alpha-synuclein protein with a low dosage in vitro, levodopa is selected as a positive drug in an in-vivo experiment, it is proved that the compound can relieve dyskinesia caused by the Parkinson's disease, and the compound can be applied to drugs for relieving symptoms of the Parkinson's disease.
Resumen de: CN121398818A
The present invention provides methods for treating obsessive-compulsive disorder (OCD) and OCD-related disorders (somatic deformation disorder, hoarding disorder, depilation disorder), scratch (skin scratching) disorder, substance/drug induced obsessive-compulsive disorder and related disorders, obsessive-compulsive disorder and related disorders caused by another medical condition, and OCD-related disorders. And other specified and unspecified obsessive-compulsive disorders and related disorders); a twitch disorder, including Tourette Syndrome; autism spectrum disorder (ASD); and glutamate excitatory toxicity related disorders, including amyotrophic lateral sclerosis (ALS); parkinson's disease; traumatic brain injury; multiple sclerosis; huntington's disease; and schizophrenia, the method comprising administering an effective amount of a histamine type 1 receptor agonist and/or a histamine type 3 receptor antagonist, the invention also relates to a preparation method of the compound, such as betahistine or pharmaceutically acceptable salts, analogs, metabolites, prodrugs, derivatives, metabolites, co-crystals, modifiers, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers thereof.
Resumen de: CN121371074A
The invention relates to the technical field of traditional Chinese medicines, in particular to application of a traditional Chinese medicine composition in preparation of a medicine for preventing and treating motor symptoms of Parkinson's disease. The traditional Chinese medicine composition is prepared from the following raw material medicines: 15-20 parts of rehmannia, 10-15 parts of eucommia ulmoides, 6-12 parts of gastrodia elata, 12-18 parts of concha haliotidis, 10-15 parts of parasitic loranthus, 12-18 parts of astragalus membranaceus, 6-12 parts of angelica sinensis, 5-8 parts of cassia twig and 10-15 parts of radix paeoniae alba. The composition is scientific and reasonable in component compatibility, has the effects of tonifying the kidney, calming the liver, benefiting qi, nourishing blood, regulating and tonifying the spleen and the stomach, relieving dizziness, activating blood, clearing damp and dredging collaterals, is safe to take and good in curative effect, can be effectively used for preventing and treating motor symptoms of the Parkinson's disease, and has a more remarkable treatment effect compared with other prescriptions.
Nº publicación: US20260021100A1 22/01/2026
Solicitante:
ARIBIO CO LTD [KR]
SK CHEMICALS CO LTD [KR]
ARIBIO CO., LTD,
SK CHEMICALS Co., Ltd
Resumen de: US20260021100A1
The present invention provides methods for reducing amyloid beta formation and for treating diseases associated with the accumulation of amyloid beta. The present invention provides (1) A β aggregation inhibition by A β Oligomer/Fibril formation inhibition, (2) BACE-1 reduction through β-Amyloidogenic Processing inhibition, (3) increased cerebral blood flow, (4) activation of Neuronal cell Death inhibition and Neurogenesis, Synaptogenesis, Angiogenesis promotion, (5) DKK-1 inhibition by Wnt Signaling and Aβ production Positive Feedback Loop for inhibition of APP to suppress Aβ accumulation, (6) Autophagy activation by cells, by providing Mirodenafil, Sildenafil, Vardenafil, Tadalafil, Udenafil, Dasantafil, and Avanafil and a Pharmaceutically Acceptable Salt, Solvate, and Hydrate in selected compounds key of ingredient containing drug compound composition, and this with the treatment method provided.
BOPI
Sede Electrónica
